GlassScriptPhysician profile
Jaskaren K Dhillon
NPI 1003233057
$7,784.46
in general payments reported to CMS, 2019-2025
49 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2021: $1,897 · 2022: $1,356 · 2023: $1,502 · 2024: $1,008 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,253 · Travel and Lodging: $11.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,253.45 |
| Travel and Lodging | $11.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,778.92 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $447.29 | 2021-2025 | Nuplazid |
| Ucb, INC. | $423.46 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Neurocrine Biosciences, INC. | $356.77 | 2021-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $315.32 | 2023-2025 | |
| Eisai INC. | $313.08 | 2021-2025 | |
| Lilly USA, LLC | $249.97 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $241.38 | 2021-2024 | Austedo Xr, Austedo |
| Medtronic, INC. | $241.29 | 2025 | Percept PC Brainsense |
| Amneal Pharmaceuticals LLC | $217.15 | 2019-2024 | Rytary |
| Sk Life Science, INC. | $202.09 | 2021-2024 | |
| Amgen INC. | $194.80 | 2021-2023 | Aimovig |
| Novartis Pharmaceuticals Corporation | $189.53 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $185.89 | 2021 | |
| Alexion Pharmaceuticals, INC. | $185.09 | 2021-2023 | Ultomiris |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $172.21 | 2021-2023 | Vumerity, Avonex, Plegridy |
| Genzyme Corporation | $163.22 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.23 | 2023-2025 | Hyqvia, Gammagard |
| Jazz Pharmaceuticals INC. | $131.16 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.09 | 2022 | |
| Lundbeck LLC | $110.99 | 2021-2024 | Vyepti |
| Acorda Therapeutics, INC | $109.64 | 2019-2022 | |
| Csl Behring | $105.07 | 2021-2025 | Hizentra |
| Abbott Laboratories | $103.47 | 2024-2025 | Infinity, Supera |
| Supernus Pharmaceuticals, INC. | $101.79 | 2022-2025 | Qelbree |
| Merz Pharmaceuticals, LLC | $87.01 | 2023-2024 | Xeomin |
| Grifols USA, LLC | $85.61 | 2021-2022 | |
| Kyowa Kirin, INC. | $83.87 | 2021 | |
| Medtronic USA, INC. | $77.25 | 2019 | |
| Averitas Pharma INC. | $73.68 | 2023 | Qutenza |
| Argenx US, INC. | $62.39 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Boston Scientific Corporation | $61.52 | 2022-2023 | Vercise |
| Baxter Healthcare | $49.79 | 2023 | Floseal |
| Sunovion Pharmaceuticals INC. | $47.06 | 2021 | |
| Depuy Synthes Sales INC. | $46.81 | 2021 | |
| Avion Pharmaceuticals | $44.45 | 2022-2023 | Dhivy |
| Janssen Pharmaceuticals, INC | $41.77 | 2021-2022 | |
| Allergan, INC. | $37.63 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $24.49 | 2021 | |
| Genentech USA, INC. | $23.97 | 2022 | |
| Axsome Therapeutics, INC. | $18.71 | 2025 | Symbravo |
| Scilex Pharmaceuticals INC. | $17.26 | 2023 | Ztlido |
| Emd Serono, INC. | $16.51 | 2023 | Mavenclad |
| Upsher-Smith Laboratories LLC | $14.48 | 2021 | |
| Inspire Medical Systems, INC. | $14.18 | 2024 | Inspire |
| Impel Pharmaceuticals INC. | $14.14 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $12.14 | 2021 | |
| Ge Healthcare | $11.70 | 2021 | |
| Insightec,INC | $6.14 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaskaren Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.